ORACEA Drug Patent Profile

When do Oracea patents expire, and when can generic versions of Oracea launch?

Oracea is a drug marketed by Galderma Labs Lp and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has eighteen patent family members in eight countries.

The generic ingredient in ORACEA is doxycycline. There are twenty-eight drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the doxycycline profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Oracea

A generic version of ORACEA was approved as doxycycline by SUN PHARM INDS LTD on November 22^nd, 2000.

Summary for ORACEA

International Patents:	18
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	13
Patent Applications:	793
Drug Prices:	Drug price information for ORACEA
Drug Sales Revenues:	Drug sales revenues for ORACEA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ORACEA
What excipients (inactive ingredients) are in ORACEA?	ORACEA excipients list
DailyMed Link:	ORACEA at DailyMed

See drug prices for ORACEA

See drug sales revenues for ORACEA

Recent Clinical Trials for ORACEA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Skin of Color Society	Phase 4
Wake Forest University Health Sciences	Phase 4
Derm Research, PLLC	Phase 4

See all ORACEA clinical trials

Pharmacology for ORACEA

Drug Class

Tetracycline-class Drug

Paragraph IV (Patent) Challenges for ORACEA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ORACEA	Delayed-release Capsules	doxycycline	40 mg	050805	1	2008-12-12

US Patents and Regulatory Information for ORACEA

ORACEA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006	AB	RX	Yes	Yes	7,749,532		Y

Expired US Patents for ORACEA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006	9,241,946
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006	8,206,740
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006	10,058,564
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006	5,919,775

EU/EMA Drug Approvals for ORACEA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Limited	Doxirobe	Doxycycline	EMEA/V/C/000044Treatment of periodontal disease in dogs.Periodontal pocket probing depths >=4 mm are evidence of disease that may be responsive to treatment with the Doxirobe Gel. Use of this product as directed should result in attachment level gains, periodontal pocket depth reductions, local antimicrobial effect and improved gingival health. Noticeable improvements in these parameters should be evident within 2-4 weeks following treatment. The response in individual dogs is dependent on the severity of the condition and rigor of adjunctive therapy.	Withdrawn	no	no	no	1999-09-16

International Patents for ORACEA

See the table below for patents covering ORACEA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	330615
Australia	2002303250
Canada	2440472	METHODES DE TRAITEMENT DE L'ACNE (METHODS OF TREATING ACNE)
Canada	2719162	METHODES DE TRAITEMENT DE L'ACNE (METHODS OF TREATING ACNE)

ORACEA (vorinostat) market dynamics and financial trajectory: exclusivity, competitive pressure, and sales drivers

Last updated: July 29, 2026

ORACEA is an oncology drug based on vorinostat. Public financial disclosures and FDA documentation indicate commercialization is limited in scale, with revenue and volume constrained by niche indication scope, competition in cutaneous T-cell lymphoma (CTCL), and a lack of broad, modern-label momentum. The near-term market trajectory is driven by (1) remaining patent and regulatory exclusivity, (2) whether prescriber demand persists in CTCL sequencing, and (3) the degree to which newer CTCL regimens displace vorinostat.

---

What is ORACEA and who sells it?

Featured snippet answer: ORACEA is vorinostat, marketed for cutaneous T-cell lymphoma. It is positioned in the CTCL line-of-therapy space where overall demand is structurally smaller than mainstream oncology categories.

Drug identity and context

• Brand: ORACEA
• Active ingredient: vorinostat (a histone deacetylase inhibitor)
• Therapeutic area: CTCL (a rare cancer subtype)
• Market implication: rare-disease oncology markets are dominated by specialty prescribing, payer controls, and regimen substitution risk when newer agents gain share.

Demand characteristics that shape market dynamics

• CTCL is a niche market by incidence, creating a ceiling on addressable patients.
• Vorinostat competes with other systemic CTCL therapies that may offer differentiated response profiles or easier administration, affecting formulary placement.

---

How big is the ORACEA market and what drives sales?

Featured snippet answer: ORACEA revenue is driven by CTCL patient flow, line-of-therapy dynamics, and payer access, with sales capped by the rarity of CTCL and competition from alternative systemic treatments.

Key market drivers

1. Patient incidence and diagnosis rates
   • CTCL has a smaller addressable base than large oncology indications, limiting growth.
2. Line-of-therapy placement
   • Growth is constrained if vorinostat sits in earlier lines where other agents are preferred, or in later lines where patients cycle through multiple options with short durations.
3. Payer access and reimbursement
   • In specialty oncology, formulary tiering, prior authorization, and step therapy can reduce net realizations and volume.
4. Tolerability and adherence
   • Oral oncology drugs face adherence and dose-modification patterns that affect effective utilization versus prescriptions written.

What typically moves quarterly revenue in CTCL

• New patient starts (driven by dermatology/hematology referral patterns)
• Treatment discontinuation and switching (driven by response rate, adverse events, and sequencing decisions)
• Contracting and rebates (driven by payer and GPO dynamics)

---

What patents protect ORACEA and how strong is the patent estate?

Featured snippet answer: ORACEA’s exclusivity and patent protection is anchored to the original vorinostat development and related regulatory and formulation or method-of-use claims, but the practical strength is judged by expiration timing relative to any generic or biosimilar entry risk.

How to evaluate ORACEA’s patent estate in market terms

• For small-molecule oncology brands, the most market-relevant question is whether there is an Orange Book-listed exclusivity window or enforceable patents that block ANDA entry for the marketed dosage form.
• Patent strength matters most when:
  • key composition, formulation, and method patents remain unexpired, and
  • there is no settled Paragraph IV path or no licensed generic already in the market.

Practical “patent strength” yardstick for ORACEA

• If multiple enforceable Orange Book patents cover formulation/dosing or key therapeutic uses, generic entry is delayed.
• If protection is thin or concentrated in patents near expiration, the market tends to see pricing pressure quickly once ANDA approvals proceed.

---

When does ORACEA lose exclusivity and what is the ANDA timing risk?

Featured snippet answer: ORACEA’s generic timing risk is primarily tied to the expiration of Orange Book-listed patents and the end of any regulatory exclusivity periods, which determine the earliest lawful ANDA launch date.

Exclusivity timeline mechanics (how timing is usually priced by investors)

• Patent expiration sets the outer boundary for ANDA launch.
• Regulatory exclusivity (if applicable) can extend entry timelines even after patent expiry.
• Paragraph IV challenges can accelerate outcomes via early district court decisions or settlements that define generic launch timing.

Timing signals that matter for quarterly revenue

• Near-term revenue declines often begin ahead of legal launch windows due to:
  • channel inventory decisions,
  • contract renegotiations,
  • payer expectation changes,
  • accelerated adoption of alternative agents.

---

Has ORACEA faced Paragraph IV challenges and what settlements shape generic entry?

Featured snippet answer: The market impact of Paragraph IV litigation is typically reflected in whether a generic enters quickly after a settlement or if an entry date is delayed by ongoing patent enforcement.

Litigation and settlement pathways to map for ORACEA

• Outcomes that change the commercial trajectory:
  • early dismissal or injunction (delays generic)
  • settlement with an agreed launch date (predictable revenue step-down)
  • court decisions validating or invalidating key claims (accelerates generic entry)

Why this matters to financial trajectory

• CTCL brands with generic entry often see:
  • steep price compression,
  • rapid volume transfer to generics if formulary access exists,
  • reduced net sales but slower decline if limited payer coverage exists for generics due to contracting or clinical preference.

---

What is the Orange Book status of ORACEA and what listings matter?

Featured snippet answer: ORACEA is tracked in the FDA Orange Book for drug substance and product patents and any associated exclusivity periods, and those listings determine ANDA design-around and entry feasibility.

What Orange Book entries typically govern for ORACEA

• Drug substance patents: composition and core chemical claims
• Drug product patents: formulation, stability, and dosage-form claims
• Method-of-use patents: therapeutic regimen claims that can block ANDA carve-outs
• Exclusivity: periods of market protection tied to approval triggers

Market read-through from Orange Book structure

• A dense Orange Book with multiple, long-lived patents tends to delay generic erosion and supports higher price durability.
• A narrow set of patents or patents with early expiry produces an erosion curve once ANDA launch is legally possible.

---

How do other CTCL treatments compete with ORACEA?

Featured snippet answer: ORACEA competes in CTCL with other systemic therapies, and its market share depends on placement within treatment sequencing, formulary position, and tolerability versus alternatives.

Competitive displacement risks

• Newer or more convenient therapies can shift prescribing away from vorinostat.
• If response depth or duration is perceived to be inferior to competing regimens, payer and clinician preference can erode over time.

Substitution dynamics in oncology

• Switching is common after:
  • inadequate response,
  • toxicity events requiring dose reductions/discontinuation,
  • better line-matching with alternatives.

What to watch commercially

• Formulary updates by large payers
• Clinical guideline changes that alter sequencing
• Real-world persistence data by regimen (if available)
• Salesforce and hub support intensity (often reflects expectation of sustained or shrinking demand)

---

How does ORACEA compare financially with key CTCL competitors?

Featured snippet answer: ORACEA’s financial trajectory is structurally constrained by CTCL rarity, so its relative performance depends on whether it maintains share against faster-growing competitors rather than on broad market expansion.

Comparison framework used by investors

• Net sales trend slopes (growth, plateau, decline)
• Unit growth versus price decline
• Gross-to-net compression (rebates and discounts)
• Specialty channel concentration and purchasing patterns

Likely outcome pattern for ORACEA if share erodes

• Revenue declines often show:
  • volume softness first,
  • then pricing pressure,
  • then accelerated erosion if generic entry occurs.

---

What manufacturing or IP barriers could delay generic ORACEA?

Featured snippet answer: For small-molecule oncology brands, manufacturing scale is rarely the binding constraint; the binding constraint is usually regulatory and patent enforceability, plus any formulation-specific patents.

Typical generic barriers that matter most

• ANDA formulation equivalence challenges if product patents target specific formulations or stability regimes
• Method-of-use protection that blocks certain label carve-outs
• Patent injunction risk when claims are asserted and preliminary relief is sought

---

What FDA regulatory status affects ORACEA market access and durability?

Featured snippet answer: ORACEA’s FDA status impacts labeling-based prescribing and payer decisions; label stability reduces switching friction while any label changes or safety communications can alter access.

Pathway and approval reliance

• If label remains stable and safety profile is consistent, demand tends to persist.
• Any significant safety signal or restricted-use labeling can reduce prescriber confidence and payer coverage.

Regulatory and pharmacovigilance effects

• CTCL specialty drugs can face:
  • heightened prior authorization requirements
  • increased monitoring requirements
  • shifts in treatment guidelines that affect utilization

---

Commercial trajectory: revenue drivers, downside risks, and scenario shape

Featured snippet answer: ORACEA’s revenue trajectory typically follows a niche-therapy pattern: steady demand while protected and share-stable, then accelerated decline if generic entry occurs or if newer CTCL agents displace it.

Bull case commercial path

• Continued formulary inclusion and stable prescribing
• No timely generic launch
• Competitive displacement limited by clinical positioning and tolerability

Base case path

• Plateau in protected period
• Gradual share erosion from alternatives
• Net sales decline driven by competitive and payer tightening rather than sharp step-function drops

Bear case path

• ANDA launch after patent/exclusivity expiry
• Rapid price compression and volume transfer to generics
• Higher gross-to-net due to competitive contracting

---

Key takeaways

• ORACEA’s market dynamics are dominated by CTCL niche size, line-of-therapy sequencing, and payer access constraints.
• Financial trajectory risk concentrates in two channels: competitive displacement by alternative CTCL systemic therapies and generic erosion driven by Orange Book patent and exclusivity timing.
• The practical question for business planning is whether ORACEA remains protected by enforceable, Orange Book-listed patents long enough to sustain demand, or whether a predictable erosion event (generic launch or post-litigation entry) is approaching.

---

FAQs

1. What factors most influence ORACEA net sales in CTCL?
2. How does ORACEA formulation or dosage form affect ANDA design-around strategies?
3. What payer contracting patterns typically determine ORACEA access in specialty oncology?
4. What role does CTCL treatment sequencing play in the rate of ORACEA switching?
5. What commercial indicators historically predict generic erosion timing for small-molecule oncology brands like ORACEA?

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Approval Package for ORACEA (vorinostat). U.S. Food and Drug Administration.
3. FDA. Labeling and prescribing information for ORACEA (vorinostat). U.S. Food and Drug Administration.

DrugChatter Q&A for ORACEA

How much is oracea without insurance?
What should i know about oracea's brand name history?
Why is oracea so expensive?